AELCLÉS presents report highlighting the high socioeconomic impact of oncohaematological diseases in SpainMPE19 February 2026
MPE response to EMA consultation on their “Reflection paper on patient experience data (PED)”Sin categoría3 February 2026
US Food and Drug Administration (FDA) issues draft guidance on minimal residual diseaseAccess28 January 2026
Watch our webinar “How are costs and medicine effectiveness part of decision-making in medicine access?”Access, Videos15 October 2025
Highlights from the International Myeloma Society (IMS) annual meeting 2025Conferences, Myeloma24 September 2025
